Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Lung Neoplasms 6Solid Tumor 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Recurrence 1Rare Tumour 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1NSCLC 1Meningeal Carcinomatosis 1Brain Neoplasms 1

Interventions

Fluorodeoxyglucose F18 2toripalimab 1spartalizumab 1sintilimab 1osimertinib 1olaparib 1apatinib 1Ink 1Histocompatibility Testing 1Carboplatin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Solid Tumor × osimertinib × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡